US Patent 10,881,624 Landscape: Claim Scope, Enabling Boundaries, and US Competitive/Exclusivity Exposure for Bupropion–Dextromethorphan Co-Administration
Executive summary: US Patent 10,881,624 claims a tightly parameterized pharmacokinetic (PK) and phenotype-conversion method in the US: bupropion + dextromethorphan twice daily for ≥8 consecutive days in specific dose ranges, in extensive metabolizer subjects, producing dextromethorphan exposure (Day 5 and Day 8) that is at least 10x (Day 5) and at least 20x (Day 8) relative to dextromethorphan alone, with additional dependent claim hooks for metabolizer conversion to poor/intermediate, specific PK thresholds (AUC0-12, Cmax), and single solid co-formulations. The estate is claim-shaped around: (1) the bupropion-mediated CYP2D6 inhibition phenotype shift, (2) schedule and duration (twice daily, ≥8 days), and (3) numerical PK readouts that set direct infringement levers for both litigation and generic entry risk.
What is US Patent 10,881,624 claiming for bupropion + dextromethorphan co-administration in the US?
Core independent claim (claim 1) in plain technical terms
Claim 1 is a method of increasing dextromethorphan plasma level via co-administration with bupropion, under a defined PK-performance target and subject metabolism status.
Key claim elements (infringement-critical)
- Route/schedule: Co-administer dextromethorphan + bupropion twice a day for at least eight consecutive days.
- Dose window for bupropion: ~200 mg/day to ~300 mg/day total bupropion.
- Patient phenotype: The subject is an extensive metabolizer of dextromethorphan.
- Treatment context: Subject is in need of treatment with dextromethorphan (broad clinical intent language).
- Comparative PK benchmark: On Day 5 (fifth day of co-administration), the dextromethorphan plasma level after twice-daily dosing must be:
- ≥10x the plasma level achieved by administering the same amount of dextromethorphan twice daily without bupropion.
- Efficacy on trough exposure: On Day 8, the co-administration must produce a Cmin at least 20x versus dextromethorphan alone for the same eight-day schedule.
Readouts and why they matter
- Claim 1 uses both an early exposure metric (Day 5 plasma level, at least 10x) and a steady-state trough metric (Day 8 Cmin, at least 20x). That combination is designed to capture both onset and sustained inhibition effects.
- The comparison is within-subject design language (“would be achieved” by administering the same amount without bupropion). In litigation, this is typically modeled with PK bridging and/or comparative studies.
What do dependent claims 2 through 12 add to the scope of US 10,881,624?
Day-5 potency tightening
- Claim 2: Raises the Day 5 requirement from claim 1’s ≥10x to ≥20x.
Single dosage form requirement
- Claims 3–5: Narrow to cases where bupropion and dextromethorphan are administered in a single dosage form.
- Claim 4: Single dosage form must be solid.
- Claim 5: The single dosage form administers ~40 mg to ~70 mg dextromethorphan.
Dose-range specificity for dextromethorphan
- Claim 6: ~80 mg/day to ~140 mg/day dextromethorphan.
- Claim 7: ~60 mg/day to ~100 mg/day dextromethorphan.
- Claim 8: ~200 mg/day to ~250 mg/day bupropion.
- Claim 9: ~250 mg/day to ~300 mg/day bupropion.
Explicit PK numeric thresholds
- Claim 10: Day-8 AUC0-12 is ≥400 ng·hr/mL.
- Claim 11: Day-8 AUC0-12 is ~700 to ~1000 ng·hr/mL.
- Claim 12: Day-8 Cmax is ~70 to ~100 ng/mL.
Scope implication
Dependent claims act as alternative infringement routes: even if a product avoids one metric (example: misses a specific Cmin multiple), it may still meet an AUC or Cmax threshold, or fall within the single-solid formulation constraint set.
How does claim 13 expand US 10,881,624 from PK boosting to metabolism phenotype conversion?
What claim 13 changes
Claim 13 is broader in clinical framing and shifts the comparative endpoint to overall exposure on Day 8.
Claim 13 elements
- Dose window (combined):
- Dextromethorphan: ~60 mg/day to ~140 mg/day
- Bupropion: ~200 mg/day to ~300 mg/day
- Schedule/duration: Co-administer twice daily for at least eight consecutive days.
- Conversion effect: Effective for converting the human from:
- extensive metabolizer to poor or intermediate metabolizer of dextromethorphan.
- Day-8 comparative PK: On Day 8, AUC0-12 is at least 20x vs the AUC achieved by dextromethorphan alone for the same dosing regimen (same amount, twice daily, eight days), without bupropion.
Scope implication
Claim 13 creates a second infringement theme: not just PK enhancement, but CYP2D6 functional phenotype conversion proxies tied to AUC0-12 performance.
What do dependent claims 14 through 19 add to phenotype-conversion methods?
Metabolizer category tightening
- Claim 14: Converts to poor metabolizer specifically.
Further dextromethorphan dose narrowing
- Claim 15: Dextromethorphan at ~85 mg/day to ~95 mg/day.
Single solid co-formulation
- Claim 16: Bupropion + dextromethorphan in a single solid oral dosage form.
Day-8 PK ranges and minimums
- Claim 17: Day-8 AUC0-12 is ~700 to ~1000 ng·hr/mL.
- Claim 18: Day-8 Cmax ≥ 50 ng/mL.
- Claim 19: Day-8 Cmax ≥ 70 ng/mL.
Scope implication
Claims 14–19 are positioned to capture products that operationalize the regimen through fixed-dose combination solids, and then satisfy PK outcome bands consistent with broad phenotype conversion.
What is the likely technical boundary set by “extensive metabolizer” and “twice daily for at least eight days”?
The claim language forces a specific patient metabolic starting point and a specific treatment duration/schedule.
-
Extensive metabolizer limitation (claim 1):
- The method is expressly directed to humans who are extensive metabolizers at baseline.
- In infringement analysis, this creates a potential defense angle for any product label focusing on other genotypes/phenotypes, or any study design not aligned to “extensive metabolizer” inclusion.
-
≥8 consecutive days (claims 1 and 13):
- This targets a chronic co-administration window that matches a steady-state PK period and supports the use of Day 8 metrics.
- It also makes short-term dosing a potential design-around for some competitors, unless they can still satisfy “at least eight consecutive days.”
-
Twice daily:
- Locks dosing frequency. Once-daily schedules could be designed to avoid the “twice a day” element unless they can still meet claim language through dosing equivalence that meets the numeric “twice a day” requirement.
How do the Day-5 and Day-8 comparative benchmarks shape infringement risk?
Claim 1 provides a two-stage benchmark
- Day 5 plasma level: ≥10x vs dextromethorphan alone.
- Day 8 Cmin: ≥20x vs dextromethorphan alone.
Claim 13 provides a Day-8 single metric
- Day 8 AUC0-12: ≥20x vs dextromethorphan alone.
Practical enforcement lever
- Numerical multipliers (10x, 20x) and numeric thresholds (AUC0-12 bands; Cmax bands) give litigators and regulatory strategists tangible endpoints for:
- PK study design and bridging.
- Product testing to assess whether the regimen meets claimed performance.
What formulation and dosage-form constraints exist in US 10,881,624?
The claims are not purely “composition of matter.” They are method claims with optional formulation constraints via dependent claims.
Single dosage form hooks
- Claim 3: single dosage form.
- Claim 4: solid.
- Claim 16: single solid oral dosage form.
Dextromethorphan content (dependent claim 5)
- ~40 mg to ~70 mg dextromethorphan in the single dosage form.
Dose windows for dextromethorphan and bupropion
- Dextromethorphan:
- ~60–100 mg/day (claim 7)
- ~80–140 mg/day (claim 6)
- ~85–95 mg/day (claim 15)
- Bupropion:
- ~200–250 mg/day (claim 8)
- ~250–300 mg/day (claim 9)
- plus overarching ~200–300 mg/day (claim 1)
Scope implication
Even if a competitor avoids a “single solid co-formulation,” independent claim 1 and 13 still can be implicated by co-administration (two separate products) because the independent claims do not require co-formulation.
How does claim structure affect design-around options for generics and branded competitors?
Design-around variables tied to elements
- Dosing schedule: Avoid “twice daily” or “≥8 consecutive days.”
- Bupropion dose window: Avoid ~200–300 mg/day.
- Dextromethorphan dose window: Avoid ~60–140 mg/day (or the dependent narrower windows if targeting those claims).
- Comparator effect: Claims require numeric superiority versus dextromethorphan alone. Avoid achieving the ≥10x Day 5 and/or ≥20x Day 8 metrics.
- Patient inclusion: Avoid “extensive metabolizer” populations (not always feasible if clinically indicated, but it matters for directed method claims).
- Single dosage form: To reduce risk against dependent claims (3–5, 16), competitors can separate dosing into two dosage forms. Risk against independent claims remains.
Litigation posture implication
Because independent claims do not require the “single dosage form,” co-administration with any bupropion dosing that hits the specified PK outcomes remains the central infringement risk.
What patent landscape features typically cluster around this type of PK-boosting regimen (and how to map them to this claim set)?
Even without additional patent numbers provided here, the claim set signals a landscape with likely adjacent patent categories:
- CYP2D6 inhibitor + dextromethorphan exposure increase
- Method claims around co-administration (bupropion as the inhibitor) and specific PK readouts (Cmin, AUC0-12, Cmax).
- Phenotype conversion claims
- Methods converting extensive metabolizers to poor or intermediate metabolizers, often tied to CYP2D6 activity proxies.
- Dose-ranging and regimen-specific claims
- Narrow windows for bupropion (200–300 mg/day) and dextromethorphan daily dose (60–140 mg/day), with additional dependent narrowing.
- Fixed-dose combination (FDC) formulations
- Claims for single solid oral dosage forms with specific dextromethorphan content.
- Biomarker-linked or genotype-linked dependent claims
- “Extensive metabolizer” language suggests there may be related claims or evidence around metabolizer stratification.
Where would you expect US Orange Book listings and Paragraph IV litigation to intersect this claim set?
Intersection points
- The claim is method-based but depends on dosing regimens and drug exposure outcomes, which commonly align with:
- NDA/BLA-labeled dosing instructions.
- Generics that attempt to reproduce the PK boost via the same inhibitor co-administration.
- If a branded program includes a fixed-dose combination or an approved regimen reflecting these doses and schedule, then:
- Orange Book could list relevant patents tied to that product (method of treatment, formulation, or use claims).
- Paragraph IV challenges often target formulation/use patents, while disputes focus on whether the proposed label/dosing would practice the claimed regimen.
Practical outcome
- The strongest “entry risk” is for applicants seeking to market a regimen (single product or co-packaged approach) that matches the same schedule/dose and achieves equivalent or superior dextromethorphan exposure.
How strong is the patent estate for US 10,881,624 based on the claim mechanics you provided?
Based purely on claim structure (not on family count, prosecution history, or cited references), US 10,881,624’s strength profile is:
High-value features
- Clear quantitative performance criteria (10x, 20x; AUC0-12 thresholds; Cmax bands; Cmin multiple).
- Regimen specificity (twice daily, ≥8 days, Day 5 and Day 8 readouts).
- Patient metabolic starting point (“extensive metabolizer”) plus a defined conversion effect (claim 13).
- Formulation-dependent fallbacks via single solid oral dosage form and dextromethorphan content range.
Vulnerability vectors (inherent to this type of claim)
- Proof burden: Infringement often requires PK evidence under controlled conditions and correct comparator design.
- Potential non-literal avoidance: competitors could shift dose/schedule slightly or adjust bupropion exposure to miss the multipliers.
- Non-infringement via label/population: if the clinical regimen avoids “extensive metabolizers,” claim 1’s population anchor could be contested.
Key Takeaways
- US 10,881,624 is a quantitative PK and phenotype-conversion method for boosting dextromethorphan plasma levels by co-administering bupropion twice daily for ≥8 days in ~200–300 mg/day bupropion and specific dextromethorphan dose windows.
- Infringement hinges on numerical superiority vs dextromethorphan alone: ≥10x Day 5 plasma level and ≥20x Day 8 Cmin (claim 1), or ≥20x Day 8 AUC0-12 plus phenotype conversion (claim 13).
- Dependent claims add single solid dosage form and multiple numeric PK bounds (AUC0-12 400 ng·hr/mL minimum; 700–1000 band; Cmax 50–100 ng/mL).
- The claim set is structured to support both regimen-based enforcement (independent claims) and formulation/combination-specific enforcement (dependent claims).
FAQs
- How do “Cmin on the eighth day” and “AUC0-12 on the eighth day” change test/bridge study design for infringement or design-around?
- Do dependent claims requiring a single solid dosage form limit infringement only to fixed-dose combinations?
- Can a competitor avoid infringement by using a different bupropion total daily dose just outside 200–300 mg/day while keeping the same twice-daily schedule?
- What role does the “extensive metabolizer” limitation play in claim 1 for label and patient selection strategy?
- Which claims are strongest for asserting conversion to poor versus intermediate metabolizer categories?
References
- User-provided claim text for US Patent 10,881,624 (claims 1–19).
